Visiongain has released its new Peptide Contract Manufacturing Market Report 2026-2036, forecasting that the global market will reach US$12.88bn by 2036 from US$3.89bn in 2026.

The market is forecast to expand at a compound annual growth rate (CAGR) of 12.7% between 2026 and 2036, driven by rapidly increasing demand for GLP-1 and metabolic peptide therapies, expanding clinical pipelines for complex peptide therapeutics, and growing outsourcing to specialist CDMOs with integrated API-to-drug-product capabilities.

Key Market Growth Drivers & Industry Transformations

Rapidly Increasing Demand for GLP-1 and Other Metabolic Peptide Therapies: Growing demand for peptide-based treatments for diabetes, obesity and weight management is creating substantial requirements for large-scale peptide API manufacturing. GLP-1 receptor agonists require complex synthesis, purification, analytical control and reliable commercial-volume production, encouraging pharmaceutical companies to secure long-term CDMO capacity. CordenPharma announced an approximately 900 million euro investment to expand its peptide platform in the United States and Europe, including additional Colorado capacity intended to address GLP-1 demand. The investment followed multiple long-term manufacturing contracts valued at approximately 3 billion euros, demonstrating how metabolic-peptide demand is generating capacity investment and additional outsourcing expenditure.

Expansion of Clinical Pipelines for Complex Peptide Therapeutics: Peptide drug pipelines are expanding beyond established metabolic indications into oncology, cardiovascular diseases, infectious diseases, central nervous system disorders and rare diseases. New candidates increasingly incorporate longer sequences, non-natural amino acids, conjugation, cyclisation and other structural modifications intended to improve potency, stability and pharmacokinetic performance. These characteristics increase process-development, purification and analytical requirements, creating demand for specialist peptide CDMOs. Bachem’s CMC Development sales increased by 29.7% to CHF304.0 million in 2025, driven by strong peptide-based development projects, indicating increasing pre-commercial development activity where sponsors require process optimisation, impurity control and GMP clinical supply.

Movement Towards Large-Scale Solid-Phase Peptide Synthesis: Solid-phase peptide synthesis is moving beyond predominantly clinical and speciality production towards substantially larger commercial manufacturing scales. This transition is being driven by increasing demand for GLP-1 therapies and other peptide products requiring reliable multi-kilogram and high-volume output. PolyPeptide began production using new large-scale SPPS capacity at its Braine-l’Alleud facility in Belgium in December 2024 and subsequently completed the facility’s ramp-up during 2025, achieving its target utilisation rate by end of year. This trend is encouraging peptide CDMOs to install larger synthesis equipment, expand downstream purification and establish dedicated commercial manufacturing trains.

Expansion of Integrated Peptide API-to-Drug-Product Services: A substantial opportunity exists for CDMOs capable of supporting peptide programmes from process development and API synthesis through formulation, fill-finish and packaging. Peptide developers frequently use separate suppliers for active ingredients and finished dosage forms, creating additional technology-transfer, scheduling, testing and quality-management requirements. Integrated services can reduce these interfaces and support a more coordinated transition from clinical development to commercial supply. This opportunity is particularly relevant to injectable metabolic peptides and emerging oral peptide products, which require specialised formulation, stability and delivery capabilities in addition to API manufacturing.

What This Means for the Peptide Contract Manufacturing Market

The peptide contract manufacturing market is entering a period of accelerated structural growth as GLP-1 and metabolic peptide demand drives large-scale capacity expansion, pipeline diversification into oncology and CNS disorders creates demand for specialist process development and purification expertise, and pharmaceutical and biotechnology companies increasingly rely on CDMOs for integrated end-to-end services. CDMOs combining large-scale solid-phase synthesis capability, integrated API-to-drug-product services, advanced automation, and strong regulatory track records are best positioned to secure long-term commercial contracts over the next decade.

Scope of the Visiongain Report

The 350-page report provides robust quantitative and qualitative analysis across all key facets of the global peptide contract manufacturing market:

By Type of Synthesis: Chemical Synthesis; Non-chemical Synthesis.

By Scale of Operation: Preclinical / Clinical; Commercial.

By Service Type: Process Development and Scale-up; Peptide API Manufacturing; Formulation and Drug Product Manufacturing; Fill-Finish and Packaging; Analytical Testing and Quality Control.

By Therapeutic Area: Oncology; Metabolic Diseases; Cardiovascular Diseases; Infectious Diseases; Central Nervous System Disorders; Other Therapeutic Areas.

By End-users: Pharmaceutical Companies; Biotechnology Companies; Generic Drug Manufacturers; Academic and Research Institutions.

By Regional & Country Markets: North America, Europe, Asia Pacific, Latin America, and MEA.

Competitive Landscape

The competitive environment includes a mix of specialist peptide CDMOs, large integrated API manufacturers, and technology platform providers with proprietary synthesis methods. Companies profiled in the report include:

• Ajinomoto Bio-Pharma Services
• Almac Group
• AmbioPharm, Inc.
• Bachem Holding AG
• Cambrex Corporation
• CordenPharma
• BCN Peptides
• CPC Scientific Inc.
• CSBio
• Hybio Pharmaceutical Co., Ltd.
• Lonza Group AG
• Olon S.p.A.
• Peptide Institute, Inc.
• Piramal Pharma Solutions
• PolyPeptide Group AG
• ScinoPharm Taiwan, Ltd.
• WuXi TIDES

Recent Developments

• 27 May 2026 – CordenPharma entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO. The acquisition expands CordenPharma’s U.S. peptide manufacturing capacity and brings Shanghai-based peptide supply into its operational footprint across 11 sites in Europe and North America.

• 12 Dec 2025 – Lupin Manufacturing Solutions announced a long-term strategic alliance with PolyPeptide Group AG, aimed at enhancing supply chain resilience, improving operational efficiency, and accelerating readiness for the rapidly expanding global peptides market, including next-generation metabolic peptide therapeutics.

• 28 Oct 2025 – Lifecore Biomedical and PolyPeptide Laboratories signed a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical customers in the U.S.

• 25 Aug 2025 – Cambrex announced that Snapdragon Chemistry expanded its API facility in Waltham, Massachusetts to further support the development and manufacturing of peptide therapies.

Related Reports

• Antibody Drug Conjugates Contract Manufacturing Market 2026-2036
• Biopharmaceuticals Contract Manufacturing Market 2026-2036
• mRNA Contract Manufacturing Market 2026-2036
• Protein Contract Manufacturing Market 2026-2036

About Visiongain

Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.

Media Contact

press@visiongain.com
+44 (0)20 7336 6100
www.visiongain.com